冯丹龙委员:从国家和省级层面共同推动心血管疾病防控体系建设

2018-03-05 袁馨晨 新华网

根据《中国心血管病报告2016》的数据显示:我国心血管病患病率仍处于持续上升阶段,估计全国约有心血管病患者2.9亿,其中高血压约2.7亿,脑卒中约1300万,冠心病约1100万。心血管病仍是中国居民疾病死亡的第一死因。


全国政协委员冯丹龙博士

根据《中国心血管病报告2016》的数据显示:我国心血管病患病率仍处于持续上升阶段,估计全国约有心血管病患者2.9亿,其中高血压约2.7亿,脑卒中约1300万,冠心病约1100万。心血管病仍是中国居民疾病死亡的第一死因。为加速建设我国心血管疾病防控体系,今年两会期间,全国政协委员冯丹龙博士呼吁,积极运用全面、科学、高质、量化的指标体系,作为国家和各省心血管疾病防控工作的重要抓手,助力健康中国。

2017年,中华医学会心血管病学分会、中国心血管健康联盟等单位收集跨多学科、多领域的专家意见,共同发布了《中国心血管健康指数(2017)》。数据显示,我国不同省份的心血管健康指数存在较大差异,其中最高分是75.4,最低分是30.2,平均分是49.4。以秦岭淮河为界,南方地区在危险因素暴露、疾病救治、政策指导方面得分较高,北方在防控情况方面颇具优势;另外,东部地区得分最高,中部和西部地区分数持平。

冯丹龙建议:

一,在国家层面,把提升心血管疾病的防治水平提高到健康中国战略支撑的高度。她指出,心血管健康指数是一个全面、科学、高质、量化的指标体系,在各省制定政策、建立体系、衡量成果方面有很大的辅助和推动作用,可以成为国家和各省心血管疾病防控工作的重要抓手。

二,在省级层面,积极将指数评估用于指导工作开展。鉴于各省在心血管健康方面存在较大差异,建议以指数为抓手,找到各省的具体可提升方向,因地制宜地制定出切实可行的心血管疾病防控工作提升策略和行动方案,对于各项行动进行有效排序,明确相关负责部门,确保有限资源的合理应用。

三,从国家和省级层面,将指数作为心血管疾病防控工作的重要抓手,并把其列为各地卫计委心血管疾病防控工作的衡量指标,定期进行评估并对结果进行公布。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-08 三生有幸9135

    学习一下谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-06 飛歌

    厉害了我的哥

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2035370, encodeId=f54120353e0cf, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Nov 17 07:21:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690007, encodeId=dbff169000e3a, content=<a href='/topic/show?id=e963266341b' target=_blank style='color:#2F92EE;'>#体系建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26634, encryptionId=e963266341b, topicName=体系建设)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d628947085, createdName=ms9203727104890838, createdTime=Fri Jul 27 19:21:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294216, encodeId=d58f2942166a, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Thu Mar 08 16:21:30 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498379, encodeId=79c314983e972, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Mar 07 14:21:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293361, encodeId=8a1829336129, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Mar 06 00:30:21 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293350, encodeId=821b293350c1, content=说的好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Mon Mar 05 23:27:21 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-05 zdvfsadb

    说的好

    0

相关资讯

Lancet Diabetes Endo:高比例的前驱糖尿病患者患心血管疾病和慢性肾脏疾病的风险更高

埃默里罗林斯公共卫生学院和美国疾病控制和预防中心的研究人员发现,高比例的前驱糖尿病患者患心血管疾病和慢性肾脏疾病的风险很高。他们的研究结果发表在“柳叶刀糖尿病与内分泌学”上。

JAHA:接受PCI治疗的退伍军人对高强度他汀类药物治疗的依从性研究

2013年美国心脏病协会的指南推荐了一部分人群接受高强度他汀类药物治疗,但是患者对指南的依从性不佳。本研究旨在评估接受过经皮冠脉介入治疗(PCI)退伍军人接受高强度他汀类药物治疗的趋势和预测因素。本研究纳入了2010年至2016年接受过PCI治疗的年龄>18岁的退伍军人,并对其人口统计学特征、并发症和PCI前后90天内的他汀类药物类型和剂量进行分析。最终共纳入了48862名退伍军人,PCI术后90

Am Heart J:BNP 5-32可作为急性心梗危险分层的二级标志物

B型钠尿肽(BNP)是急性心梗危险分层的一个标志物,近期,BNP的截断蛋白分子被发现,但其作为心梗危险分层的功能尚未阐明。本研究的目的旨在评估BNP的截断蛋白分子在心梗危险分层中的作用。本研究纳入了1078名急性心梗患者,对其血浆的BNP 5-32, BNP 4-32和BNP 3-32水平进行检测,并且随访观察患者的短期和长期预后。结果分析发现,BNP的截断蛋白分子水平是患者6个月、1年和2年发生

JAMA Cardiol:19万人横跨50年,胖了真的会“伤心”!

2018年2月28日,JAMA Cardiology在线发表了一项来自美国西北大学的研究[5]。研究提示,与体重正常的人群相比,肥胖人群心血管疾病的发病率和死亡率均明显增加,即使是超重的人群也不能幸免于难。

Eur Heart J:PCSK9基因的突变对卒中和冠心病有不同的影响

PCSK9基因的突变对低密度脂蛋白胆固醇(LDL-C)和冠心病的发生均有很大的影响,然而其对缺血性卒中(IS)的影响尚属未知。本研究对10307名IS患者和19326名正常对照对PCSK9功能缺失突变(rs11591147; R46L)和另外5个突变位点与IS和IS亚型之间的关系进行荟萃分析。结果发现rs11591147的T等位点可以降低0.5mmol/L 的LDL-C水平和23%的冠心病发病风险

Heart:抗磷脂抗体可预测感染性心内膜炎患者预后

抗磷脂(aPL)抗体可以激活血小板,并在感染性心内膜炎(IE)的发展和血栓形成中起到重要作用。本研究的目的旨在评估aPL作为预测IE患者血栓事件(EE)发生的因子的可行性。本研究纳入了Nanc-IE数据库中的186名确诊为IE的患者,在患者入组后对其进行抗心磷脂(aCL)和抗β2-糖蛋白I(β2GPI)抗体的检测。分析结果发现,在118名(63%)患者中检测到至少一次EE的发生,在31名(17%)